Hillary Moore1,2, Joshua Wechsler3,4, Carrie Frost5, Elizabeth Whiteside6, Robert Baldassano1,2, Jonathan Markowitz6,7, Amanda B Muir1,2. 1. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, The Children's Hospital of Philadelphia. 2. Department of Pediatrics, University of Pennsylvania Perelman School of Medicine, Philadelphia, PA. 3. Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Ann & Robert H. Lurie Children's Hospital of Chicago. 4. Department of Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL. 5. Division of Pediatric Research, Greenville Hospital System Children's Hospital. 6. Department of Pediatrics, University of South Carolina School of Medicine-Greenville. 7. Division of Gastroenterology and Nutrition, Greenville Hospital System Children's Hospital, Greenville, SC.
Abstract
BACKGROUND AND AIMS: The incidence and prevalence of eosinophilic esophagitis (EoE) and inflammatory bowel disease (IBD) are rising with similar patterns. Co-occurrence of both diseases in the same patient has been increasingly reported. We sought to examine the pediatric population with both EoE and IBD to better understand the epidemiology and clinical implications of this overlap. METHODS: We conducted a retrospective case-control study at 2 tertiary care children's hospitals. Subjects with both EoE and IBD were identified and compared with randomly selected controls with EoE and IBD alone in terms of: demographics, atopic conditions, IBD classification, location and phenotype of Crohn disease (CD), IBD medications, endoscopic findings, and histopathology. Descriptive statistics summarized the data. RESULTS: Sixty-seven subjects with dual-diagnosis were identified across both institutions. The prevalence of IBD in the EoE population was 2.2% and EoE in IBD was 1.5%. Subjects with both diseases were more likely to have IgE-mediated food allergy compared with IBD alone (36% vs 7%, P < 0.001). Subjects with CD-EoE were less likely to have perianal disease than CD alone (2% vs 20%, P = 0.004). There was no difference in fibrostenotic EoE between the dual-diagnosis group and EoE alone. Treatment with a TNF-alpha inhibitor (anti-TNF) for management of preexisting IBD was protective against development of EoE with a relative risk of 0.314 [95% confidence interval [CI] 0.159-0.619]. CONCLUSIONS: This is a unique population in whom the underlying pathway leading to dual-diagnosis is unclear. Concomitant atopic conditions, especially IgE-mediated food allergy, and medication exposures, particularly anti-TNFs, may help predict likelihood of developing dual-diagnosis.
BACKGROUND AND AIMS: The incidence and prevalence of eosinophilic esophagitis (EoE) and inflammatory bowel disease (IBD) are rising with similar patterns. Co-occurrence of both diseases in the same patient has been increasingly reported. We sought to examine the pediatric population with both EoE and IBD to better understand the epidemiology and clinical implications of this overlap. METHODS: We conducted a retrospective case-control study at 2 tertiary care children's hospitals. Subjects with both EoE and IBD were identified and compared with randomly selected controls with EoE and IBD alone in terms of: demographics, atopic conditions, IBD classification, location and phenotype of Crohn disease (CD), IBD medications, endoscopic findings, and histopathology. Descriptive statistics summarized the data. RESULTS: Sixty-seven subjects with dual-diagnosis were identified across both institutions. The prevalence of IBD in the EoE population was 2.2% and EoE in IBD was 1.5%. Subjects with both diseases were more likely to have IgE-mediated food allergy compared with IBD alone (36% vs 7%, P < 0.001). Subjects with CD-EoE were less likely to have perianal disease than CD alone (2% vs 20%, P = 0.004). There was no difference in fibrostenotic EoE between the dual-diagnosis group and EoE alone. Treatment with a TNF-alpha inhibitor (anti-TNF) for management of preexisting IBD was protective against development of EoE with a relative risk of 0.314 [95% confidence interval [CI] 0.159-0.619]. CONCLUSIONS: This is a unique population in whom the underlying pathway leading to dual-diagnosis is unclear. Concomitant atopic conditions, especially IgE-mediated food allergy, and medication exposures, particularly anti-TNFs, may help predict likelihood of developing dual-diagnosis.
Authors: Bartosz Malisiewicz; Carla Murer; Jana Pachlopnik Schmid; Lars E French; Peter Schmid-Grendelmeier; Alexander A Navarini Journal: Dermatology Date: 2012-02-02 Impact factor: 5.366
Authors: Evan S Dellon; Chris A Liacouras; Javier Molina-Infante; Glenn T Furuta; Jonathan M Spergel; Noam Zevit; Stuart J Spechler; Stephen E Attwood; Alex Straumann; Seema S Aceves; Jeffrey A Alexander; Dan Atkins; Nicoleta C Arva; Carine Blanchard; Peter A Bonis; Wendy M Book; Kelley E Capocelli; Mirna Chehade; Edaire Cheng; Margaret H Collins; Carla M Davis; Jorge A Dias; Carlo Di Lorenzo; Ranjan Dohil; Christophe Dupont; Gary W Falk; Cristina T Ferreira; Adam Fox; Nirmala P Gonsalves; Sandeep K Gupta; David A Katzka; Yoshikazu Kinoshita; Calies Menard-Katcher; Ellyn Kodroff; David C Metz; Stephan Miehlke; Amanda B Muir; Vincent A Mukkada; Simon Murch; Samuel Nurko; Yoshikazu Ohtsuka; Rok Orel; Alexandra Papadopoulou; Kathryn A Peterson; Hamish Philpott; Philip E Putnam; Joel E Richter; Rachel Rosen; Marc E Rothenberg; Alain Schoepfer; Melissa M Scott; Neil Shah; Javed Sheikh; Rhonda F Souza; Mary J Strobel; Nicholas J Talley; Michael F Vaezi; Yvan Vandenplas; Mario C Vieira; Marjorie M Walker; Joshua B Wechsler; Barry K Wershil; Ting Wen; Guang-Yu Yang; Ikuo Hirano; Albert J Bredenoord Journal: Gastroenterology Date: 2018-09-06 Impact factor: 22.682
Authors: Peter Capucilli; Antonella Cianferoni; Robert W Grundmeier; Jonathan M Spergel Journal: Ann Allergy Asthma Immunol Date: 2018-09-06 Impact factor: 6.347
Authors: Javier Molina-Infante; Alain M Schoepfer; Alfredo J Lucendo; Evan S Dellon Journal: United European Gastroenterol J Date: 2016-09-29 Impact factor: 4.623
Authors: Paulina Tran; Laura Gober; Elizabeth K Garabedian; Ramsay L Fuleihan; Jennifer M Puck; Kathleen E Sullivan; Jonathan M Spergel; Melanie A Ruffner Journal: Front Immunol Date: 2022-09-23 Impact factor: 8.786